Unaudited Standalone & Consolidated Financial Results For The Quarter Ended 30th June 2026 Along With Limited Review Report.

IBL Indrayani Biotech Inclusive Growth Date: 07.10.2026 BSE Limited Dept. of Corporate Services, Floor 25, P] Towers, Dalal Street, Mumbai-400001. Scrip Code: 526445 Dear Sir/Madam, Subject: Outcome of the Board Meeting 07t October, 2026. Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. With reference to our intimation letter dated September 30, 2026 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that at the meeting of Board of Directors held today i.e, on Wednesday, October 07, 2026, the Directors have inter-alia, recorded the following: 1. The approval of Unaudited Financial Results (Standalone and Consolidated) of the Company, for the quarter ended June 30, 2026, as recommended by the Audit Committee at their Meeting held today, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors have reviewed the financial results and given unmodified opinion. 2. Approved the reconstitution of the following Committees of the Board with effect from today i.e. 07t October, 2026. AUDIT COMMITTEE: S. Name of the Director Designation in Category of No Committee Directorship 1 Mr. Nangavaram Mahadevan Chairman Independent Director Ranganathan 2 Mr. Swaminathan Govindarajan Member Whole-time Director 3 Ms. Bokara Nagarajan Padmaja Member Independent Director Priyadarshini STAKEHOLDER RELATIONSHIP COMMITTEE: S. Name of the Director Designation in Category of No Committee Directorship 1 Mr. Nangavaram Mahadevan Chairman Independent Director Ranganathan 2 Mr. Swaminathan Govindarajan Member Whole-time Director 3 Ms. Bokara Nagarajan Padmaja Member Independent Director Priyadarshini Block 1, 33, SIDCO Electronic Complex, Thiru Vi Ka Industrial Estate, Guindy, Chennai 600032 Ph: +91-44-2/ 4+914-464-322750521416 | www.indrayani.com | info@indrayani.com | CIN: L40100TN1992PLC129301 Indrayani Biotech Inclusive Growth RIGHTS ISSUE COMMITTEE: S. Name of the Director Designation in Category of No Committee Directorship 1 Mr. Nangavaram Mahadevan Chairman Independent Director Ranganathan 2 Mr. Swaminathan Govindarajan Member Whole-time Director 3 Mr. Kasiraman Sayee Sundar Member Managing Director The Board Meeting commenced at 03:45 P.M. and concluded at 05:45 P.M. The necessary arrangements are in place to publish the audited financial results in the newspapers. The said financial results will also be available on company’s website https://indrayani.com and also on BSE website https://www.bseindia.com/stock- share-price /indrayani-biotechltd/indranib /526445/. Kindly take the above information on record. Thanking you, Yours faithfully, For Indrayani Biotech Limited Swaminathan Govindarajan Whole-time Director DIN: 02481041 Encl: As above Block 1, 33, SIDCO Electronic Complex, Thiru Vi Ka Industrial Estate, Guindy, Chennai 600032 Ph: +91-44-2/ 4+914-464-322750521416 | www.indrayani.com | info@indrayani.com | CIN: L40100TN1992PLC129301 VENKATESH & CO Chartered Accountants INDIA Independent Auditor’s Review Report on the Quarterly Unaudited Standalone Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors, Indrayani Biotech Limited We have reviewed the accompanying statement of unaudited standalone financial results of Indrayani Biotech Limited (‘the Company’) for the quarter ended 30™" June 2026. This statement, is the responsibility of the Company’s Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to express a conclusion these financial statements based on our review. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (“Ind AS'") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. for VenkateshC & Chartered Acu FRN : 004636 C asaraty V Partner M No : 026336 UDIN: 2602633 6BLWI0\D 6| Chennai, 7t October 2026 "SRI RANGA", New No.151, Mambalam High Road, T.Nagar, Chennai- 600 017. Telefax: 2814 4763/64/65/66 Email: audit@venkateshandco.com M/s. INDRAYANI BIOTECH LIMITED CIN : L40100TN1992PLC129301 #32 & 33 Block: I, 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032. UnAudited Standalone Statement of Profit and Loss for the year ended 30th June 2026 ( Rs in Lakhs Except EPS) S No Particulars Quarter Ended Year Ended 6/30/2026 | 3/31/2026 | 6/30/2025 3/31/2026 Income From Operations 1 Revenue from Operations 415.34 407.98 668.57 2,189.78 jig Other Income 18.77 82.06 89.16 421.25 il Total Income 434.10 490.04 757.73 2,611.03 v Expenses Cost of Materials consumed 188.91 220.15 335.28 1,065.18 Employee Benefit Expense 100.60 257.93 150.15 701.32 Finance Cost 76.11 54.17 131.93 394.61 Depreciation and amortization expense 12.30 18.27 15.25 64.26 Other expenses 36.81 -90.56 108.09 265.20 Total Expenses 414.72 459.96 740.70 2,490.57 \ Profit / (loss) before exceptional items and tax 19.38 30.09 17.03 120.46 VI Exceptional Items - - - - Add : Share of profit In Associates - - - - VII Profit / (loss) before tax 19.38 30.09 17.03 120.46 VIII |Current Tax Expense 4.88 7.69 4.26 30.44 X Deferred Tax Expense 20.05 20.05 Profit (Loss) for the period from continuing 14.50 235 12.77 69.97 operations (VII-VIII-IX) Profit (Loss) for the period from discontinued loperations XI Profit (Loss) for the period (IX-X) 14.50 235 12.77 69.97 XII |Other Comprehensive Income A (i) Items that will not be reclassified to profit or loss (i) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (i) Income tax relating to items that will be reclassified to profit or loss Total Comprehensive Income for the period (XII+XI)(Comprising Profit XIIT 14.50 235 12.77 69.97 (Loss) and Other Comprehensive Income for the period) Paid up Equity Share Capital 4,553.63 4,553.63 4,553.63 4,553.63 XV |Earnings Per Share: (1) Basic 0.03 0.01 0.03 0.15 (2) Diluted 0.03 0.01 0.03 0.15 [Notes: 1. The above Standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 07th October 2026 and have been subjected to audit by the Statutory Auditors of the company. The above results have been prepared In accordance with the Indian Accounting Standards-{IndAS) as prescribed under Section133 of the CompanieAcst 2013, read with Rule3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies( Indian Accounting Standards) Amendment Ru [Showing first 8,000 characters — download PDF for full document]